Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MOHAMMAD R BOLOURI

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1659322691
CMS profile
29086
Location
CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$733.57

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $718.00 1
Food and Beverage $15.57 1

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Biogen, Inc. $718.00 1
Teva Pharmaceuticals USA, Inc. $15.57 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MOHAMMAD R BOLOURI

NPI 1659322691 · CMS profile ID 29086

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1659322691?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MOHAMMAD R BOLOURI, NPI 1659322691, CMS profile ID 29086. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1659322691?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). MOHAMMAD R BOLOURI, NPI 1659322691, CMS profile ID 29086. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1659322691?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
MOHAMMAD R BOLOURI, NPI 1659322691, CMS profile ID 29086, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1659322691?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $733.57 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Biogen, Inc. $718.0012/17/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737274507 CMS
Teva Pharmaceuticals USA, Inc. $15.5701/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749461225 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,343.30 32
PY2020 $733.57 2
PY2021 $39.36 2
PY2022 $3,758.34 15
PY2023 $10,255.80 39
PY2024 $25,153.09 51
PY2025 $8,393.72 33

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,948,171.02 223
PY2024 Recipient $42,149.90 1
PY2024 Principal investigator $2,006,224.93 95
PY2023 Recipient $150.00 1
PY2023 Principal investigator $3,166,315.18 100
PY2022 Recipient $250.00 1
PY2022 Principal investigator $2,451,442.73 165
PY2021 Principal investigator $2,459,911.12 123
PY2020 Recipient $1,077.94 1
PY2020 Principal investigator $1,535,993.16 168
PY2019 Principal investigator $1,981,815.06 222

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

96 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $2,208.00 12/23/2024 Non-covered Recipient Entity
AMC RESEARCH
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1079017054
Principal investigator 1 GlaxoSmithKline, LLC. $97.44 12/20/2024 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1156000655
Principal investigator 1 GlaxoSmithKline, LLC. $240.00 12/20/2024 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1156000897
Principal investigator 1 GlaxoSmithKline, LLC. $87.89 12/20/2024 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1156000909
Principal investigator 1 GlaxoSmithKline, LLC. $60.00 12/20/2024 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1156001239
Principal investigator 1 GlaxoSmithKline, LLC. $57.12 12/20/2024 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1156001453
Principal investigator 1 GlaxoSmithKline, LLC. $120.00 12/20/2024 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1156001581
Principal investigator 1 GlaxoSmithKline, LLC. $120.00 12/20/2024 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1156002523
Principal investigator 1 Novo Nordisk AS $6,984.36 12/20/2024 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1096864988
Principal investigator 1 Eisai Inc. $750.00 12/17/2024 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1106529109
Principal investigator 1 Eisai Inc. $17,091.00 12/16/2024 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1106529117
Principal investigator 1 GlaxoSmithKline, LLC. $3,677.40 12/08/2024 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1156002559
Principal investigator 1 GlaxoSmithKline, LLC. $810.00 11/27/2024 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127517042
Principal investigator 1 GlaxoSmithKline, LLC. $135.00 11/27/2024 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127517046
Principal investigator 1 GlaxoSmithKline, LLC. $405.00 11/27/2024 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127526342
Principal investigator 1 GlaxoSmithKline, LLC. $54.00 11/27/2024 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127526344
Principal investigator 1 GlaxoSmithKline, LLC. $54.00 11/27/2024 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127544069
Principal investigator 1 GlaxoSmithKline, LLC. $270.00 11/27/2024 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127544071
Principal investigator 1 Novo Nordisk AS $1,962.36 11/20/2024 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1096851404
Principal investigator 1 Genentech, Inc. $4,542.00 11/19/2024 Non-covered Recipient Entity
AMC RESEARCH LLC MOHAMMAD REZA BOLOURI MD
PoM study of Brain Shuttle Gantenerumab in early AD No dispute reported 06/30/2026 1133379672
Principal investigator 1 Eisai Inc. $64,935.94 11/18/2024 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1106529113
Principal investigator 1 Eisai Inc. $47,524.50 11/18/2024 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1106529115
Principal investigator 1 GlaxoSmithKline, LLC. $13,440.61 11/15/2024 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127526352
Principal investigator 1 GlaxoSmithKline, LLC. $191.80 11/08/2024 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A DOUBLE-BLIND, DOUBLE DUMMY, RANDOMIZED, PHASE 1B, NITROFURANTOIN CON No dispute reported 06/30/2026 1127526298
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 11/08/2024 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A DOUBLE-BLIND, DOUBLE DUMMY, RANDOMIZED, PHASE 1B, NITROFURANTOIN CON No dispute reported 06/30/2026 1127526300
Principal investigator 1 GlaxoSmithKline, LLC. $130.00 11/08/2024 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A DOUBLE-BLIND, DOUBLE DUMMY, RANDOMIZED, PHASE 1B, NITROFURANTOIN CON No dispute reported 06/30/2026 1127526302
Principal investigator 1 GlaxoSmithKline, LLC. $455.00 11/08/2024 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A DOUBLE-BLIND, DOUBLE DUMMY, RANDOMIZED, PHASE 1B, NITROFURANTOIN CON No dispute reported 06/30/2026 1127526304
Principal investigator 1 Novo Nordisk AS $779.76 10/31/2024 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1096843398
Principal investigator 1 GlaxoSmithKline, LLC. $405.00 10/22/2024 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127517052
Principal investigator 1 GlaxoSmithKline, LLC. $540.00 10/22/2024 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127526346
Principal investigator 1 Eisai Inc. $39,410.10 10/17/2024 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1106529111
Principal investigator 1 GlaxoSmithKline, LLC. $270.00 10/17/2024 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127526338
Principal investigator 1 GlaxoSmithKline, LLC. $54.00 10/17/2024 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127544013
Principal investigator 1 GlaxoSmithKline, LLC. $270.00 10/17/2024 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127544017
Principal investigator 1 GlaxoSmithKline, LLC. $4,245.75 10/17/2024 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127544023
Principal investigator 1 GlaxoSmithKline, LLC. $9,990.00 10/17/2024 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127544065
Principal investigator 1 Biogen, Inc. $15,600.00 10/09/2024 Non-covered Recipient Entity
Flourish Research
A Phase 2, randomized, multicenter, two-arm, open-label study to compare the pharmacodynamics, safety, and tolerability of subcutaneous versus intravenous administration of Aducanumab (BIIB037) in participants with Alzheimer's disease No dispute reported 06/30/2026 1104836752
Principal investigator 1 Janssen Research & Development, LLC $26,576.00 10/04/2024 Non-covered Recipient Entity
AMC RESEARCH
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1079017052
Principal investigator 1 Eli Lilly and Company $89,283.00 10/02/2024 Non-covered Recipient Entity
FLOURISH RESEARCH ACQUISITION LLC
A RANDOMIZED, DOUBLE-BLINDED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEVIDALEN IN PATIENTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137359775
Recipient Eli Lilly and Company $42,149.90 09/27/2024 Covered Recipient Physician ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1137349151
Principal investigator 1 GlaxoSmithKline, LLC. $30,420.91 09/25/2024 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127544025
Principal investigator 1 GlaxoSmithKline, LLC. $270.00 09/25/2024 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127544027
Principal investigator 1 GlaxoSmithKline, LLC. $2,970.00 09/25/2024 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127544067
Principal investigator 1 Novo Nordisk AS $779.76 09/20/2024 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1096879118
Principal investigator 1 GlaxoSmithKline, LLC. $270.00 09/19/2024 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127517050
Principal investigator 1 GlaxoSmithKline, LLC. $540.00 09/19/2024 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127526306
Principal investigator 1 GlaxoSmithKline, LLC. $135.00 09/18/2024 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127517040
Principal investigator 1 GlaxoSmithKline, LLC. $5,805.00 09/18/2024 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127526350
Principal investigator 1 GlaxoSmithKline, LLC. $5,805.00 09/18/2024 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127544019
Principal investigator 1 GlaxoSmithKline, LLC. $1,080.00 09/18/2024 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127544061
Principal investigator 1 Genentech, Inc. $350.00 09/17/2024 Non-covered Recipient Entity
AMC RESEARCH LLC MOHAMMAD REZA BOLOURI MD
PoM study of Brain Shuttle Gantenerumab in early AD No dispute reported 06/30/2026 1133379670
Principal investigator 1 Novo Nordisk AS $5.05 08/30/2024 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1096730323
Principal investigator 1 Novo Nordisk AS $8.52 08/30/2024 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1096740282
Principal investigator 1 Novo Nordisk AS $19.56 08/30/2024 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1096768166
Principal investigator 1 Novo Nordisk AS $6.50 08/30/2024 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1096833478
Principal investigator 1 Novo Nordisk AS $14.76 08/30/2024 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1096856794
Principal investigator 1 GlaxoSmithKline, LLC. $1,800.00 08/27/2024 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127517038
Principal investigator 1 GlaxoSmithKline, LLC. $5,725.35 08/27/2024 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127517044
Principal investigator 1 GlaxoSmithKline, LLC. $2,250.00 08/27/2024 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127517048
Principal investigator 1 GlaxoSmithKline, LLC. $1,600.00 08/27/2024 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127544015
Principal investigator 1 GlaxoSmithKline, LLC. $8,000.00 08/27/2024 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127544021
Principal investigator 1 Novo Nordisk AS $779.76 08/21/2024 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1096778259
Principal investigator 1 Eisai Inc. $22,203.90 08/20/2024 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1106529105
Principal investigator 1 Genentech, Inc. $20,978.00 08/02/2024 Non-covered Recipient Entity
AMC RESEARCH LLC MOHAMMAD REZA BOLOURI MD
PoM study of Brain Shuttle Gantenerumab in early AD No dispute reported 06/30/2026 1133379668
Principal investigator 1 ABBVIE INC. $5,000.00 08/01/2024 Non-covered Recipient Entity
AMC RESEARCH LLC
A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer Disease No dispute reported 06/30/2026 1100732752
Principal investigator 1 Eli Lilly and Company $5,542.68 08/01/2024 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A RANDOMIZED, DOUBLE-BLINDED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEVIDALEN IN PATIENTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137352548
Principal investigator 1 Eisai Inc. $54,377.10 07/22/2024 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1106529103
Principal investigator 1 Novo Nordisk AS $4,951.44 07/22/2024 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1096816058
Principal investigator 1 GlaxoSmithKline, LLC. $14,709.60 07/18/2024 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127526348
Principal investigator 1 Eisai Inc. $2,211.61 07/15/2024 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1106529107
Principal investigator 1 GlaxoSmithKline, LLC. $3,677.40 06/25/2024 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127526340
Principal investigator 1 GlaxoSmithKline, LLC. $3,677.40 06/25/2024 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127544063
Principal investigator 1 Novo Nordisk AS $7,196.58 06/21/2024 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1096844064
Principal investigator 1 Novo Nordisk AS $7.38 06/04/2024 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1096735098
Principal investigator 1 Novo Nordisk AS $4.89 06/04/2024 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1096836712
Principal investigator 1 Eisai Inc. $45,245.70 05/21/2024 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1106529093
Principal investigator 1 Genentech, Inc. $19,575.00 05/14/2024 Non-covered Recipient Entity
AMC RESEARCH LLC MOHAMMAD REZA BOLOURI MD
PoM study of Brain Shuttle Gantenerumab in early AD No dispute reported 06/30/2026 1133379664
Principal investigator 1 Genentech, Inc. $19,451.00 05/09/2024 Non-covered Recipient Entity
AMC RESEARCH LLC MOHAMMAD REZA BOLOURI MD
PoM study of Brain Shuttle Gantenerumab in early AD No dispute reported 06/30/2026 1133379666
Principal investigator 1 Novo Nordisk AS $1,559.52 04/30/2024 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1096783431
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $8,191.54 03/29/2024 Non-covered Recipient Entity
Advarra Dba Schulman Associates Irb
Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease (TargetTau-1) No dispute reported 06/30/2026 1123475207
Principal investigator 1 Novo Nordisk AS $779.76 03/27/2024 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1096857383
Principal investigator 1 Biogen, Inc. $21,743.00 03/26/2024 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimers disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205 No dispute reported 06/30/2026 1104837113
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $44,877.01 03/26/2024 Non-covered Recipient Entity
Alzheimers Memory Center
Phase 2 PoC in Early AD Patients - A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimer s Disease (TargetT No dispute reported 06/30/2026 1123475878
Principal investigator 1 Eisai Inc. $52,961.40 03/22/2024 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1106529099
Principal investigator 1 Genentech, Inc. $3,500.00 02/23/2024 Non-covered Recipient Entity
AMC RESEARCH LLC MOHAMMAD REZA BOLOURI MD
Prevention Study No dispute reported 06/30/2026 1133379662
Principal investigator 1 Novo Nordisk AS $2,850.66 02/23/2024 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1096869263
Principal investigator 1 Eisai Inc. $1,133.52 02/12/2024 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1106529095
Principal investigator 1 Eli Lilly and Company $2,662.00 02/08/2024 Non-covered Recipient Entity
ALZHEIMER'S MEMORY CENTER
A STUDY OF HEALTH CARE USE AND COSTS IN PARTICIPANTS WITH EARLY STAGE ALZHEIMER'S DISEASE AD GERAS US No dispute reported 06/30/2026 1137353218
Principal investigator 1 Eli Lilly and Company $229,168.85 02/05/2024 Non-covered Recipient Entity
ALZHEIMER'S MEMORY CENTER
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137353556
Principal investigator 1 Eisai Inc. $37,099.80 01/26/2024 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1106529101
Principal investigator 1 Eli Lilly and Company $4,546.36 01/25/2024 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1137353880
Principal investigator 1 Eli Lilly and Company $3,690.95 01/25/2024 Non-covered Recipient Entity
ALZHEIMER'S MEMORY CENTER
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137353980
Principal investigator 1 Novo Nordisk AS $12,610.08 01/24/2024 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1096760913
Principal investigator 1 Eisai Inc. $37,382.00 01/15/2024 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1106529097
Principal investigator 1 Biogen, Inc. $389,949.00 01/09/2024 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease No dispute reported 06/30/2026 1104839520
Principal investigator 1 Eli Lilly and Company $499,247.60 01/02/2024 Non-covered Recipient Entity
ALZHEIMER'S MEMORY CENTER
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1137353472